Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?

Area of Science:

• Oncology
• Immunology
• Radiology

Background:

• Immune checkpoint inhibitor (ICI) therapy is expanding for various solid tumor stages.
• ICI efficacy relies on the complex interaction between cancer cells and the tumor immune microenvironment.
• Understanding these interactions is crucial for optimizing treatment outcomes.

Purpose of the Study:

• To highlight the role of PD-1/PD-L1 Positron Emission Tomography (PET) imaging.
• To explore the potential of these imaging tools in studying the tumor immune microenvironment.
• To assess the utility of PD-1/PD-L1 PET imaging in optimizing ICI therapy.

Main Methods:

• Utilizing PD-1/PD-L1 PET imaging as a noninvasive tool.
• Studying the tumor microenvironment in a clinical setting.
• Employing sensitive and quantitative imaging techniques.

Main Results:

• PD-1/PD-L1 PET imaging allows for in vivo assessment of immune checkpoint expression.
• These imaging techniques provide insights into the tumor immune microenvironment.
• The quantitative nature of PET imaging enables precise measurements.

Conclusions:

• PD-1/PD-L1 PET imaging is a valuable tool for studying the tumor immune microenvironment.
• These noninvasive imaging modalities show promise for optimizing ICI efficacy.
• Further research can leverage these tools to personalize cancer immunotherapy.